Ares-Serono Group presented positive Phase III data on its Rebif interferon beta-1a last week, but the data may serve more to reassure clinicians about the efficacy of beta interferon in multiple sclerosis generally than to carve a large marketing niche for Rebif.

Based on its trial, Ares-Serono plans to submit applications immediately for U.S. and European marketing approval.